Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

Shots:

  • CytomX to receive $80M up front, ~$1.6B as pre/ clinical & commercial milestones, along with royalties on sales and will be responsible for research and discovery activities, up to clinical candidate selection
  • The companies partnered for several initial programs and will utilize CytomX’s Probody therapeutic technology for CD3 bispecific targets and its expertise in targeting multiple Ab modalities to the tumor micro-environment
  • For a specified number of targets, prior to the initiation of the first clinical study, CytomX to get an option to fund a pre-determined portion of development cost and may receive a pre-specified portion of profits in the US and royalties on sales (ex-US) and may later exercise its option for co-commercialization rights in the US

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: Astellas